Clinical Utility of Genomic Profiling in the Treatment of Advanced Sarcomas: A Single-Center Experience
Authors:
- 1 December 2018
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 2 (2) , 1-8
Abstract
Purpose: Sarcomas are a diverse group of malignant tumors that arise from soft tissues or bone. For most advanced cases, there is a substantial need for improved therapeutic options and, therefore, a desire to more precisely tailor therapy in individual cases. In this study, we review our institutional experience with next-generation sequencing (NGS)–based molecular profiling for non–GI stromal tumors sarcomas, with a focus on the clinical utility of the results. Patients and Methods: We retrospectively analyzed results of NGS performed on tumors from 114 patients with a diagnosis of sarcoma. A chart review was conducted to review the clinical impact of NGS findings. Results: A median of three putatively oncogenic gene alterations were identified per tumor sample (range, 0 to 19) and at least one mutation was detected in 96.7% of tumors. Fifty-six patients (49.1%) harbored a finding that was felt to be actionable after review by a molecular tumor board. Five patients (4.4%) had a diagnosis change as a result of NGS findings. In 15 patients (13.2%), therapeutic selection was influenced by NGS findings. Four of 15 (26.7%) of the NGS-influenced systemic therapies resulted in clinical benefit. Conclusion: Putatively oncogenic mutations are readily detected in the majority of sarcomas. Genetic profiling affected the diagnosis and/or treatment approach in a sizeable minority of patients with sarcoma treated at our center. Additional study is required to determine if genetic profiling leads to improved clinical outcomes.Keywords
This publication has 9 references indexed in Scilit:
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue SarcomasCell, 2017
- Next-Generation Sequencing for Patients with Sarcoma: A Single Center ExperienceThe Oncologist, 2017
- Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.Journal of Clinical Oncology, 2017
- Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomasOncotarget, 2017
- Key Lessons Learned from Moffitt’s Molecular Tumor Board: The Clinical Genomics Action Committee ExperienceThe Oncologist, 2017
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical TrialsJournal of Clinical Oncology, 2015
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark AnalysesClinical Cancer Research, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002